Carmen Aldinger, Ph.D., MPH, joined the Multi-Regional Clinical Trials (MRCT) Center of Brigham and Women’s Hospital and Harvard in October 2014 as Program Manager. She provides oversight for the Return of Aggregate Results, Return of Individual Results, and Post-Trial Responsibilities projects as well as manages MRCT Center training projects and small scale surveys and other operational and procedural aspects of the MRCT Center.
Dr. Aldinger has almost 20 years of experience in global health, including project management and leadership, materials development and capacity building, monitoring and evaluation, collaboration and coordination. Prior to coming to the MRCT Center, she worked as Project Director and Associate Center Director at Education Development Center’s Division of Health and Human Development, Global Programs, and as independent consultant for United Nations agencies.
Dr. Aldinger has a Ph.D. in educational studies from Lesley University, a Master of Public Health in international health from Yale University and a bachelor’s degree in health education from Towson University.
Behtash Bahador is a Senior Manager at the non-profit Center for Information and Study on Clinical Research Participation (CISCRP). With a background in health communication, Behtash leads quality and compliance assurance on programs that communicate clinical trial results in plain language for patients and the public. He works directly with a wide range of industry sponsors on global implementation and aligning best practices in health communication with regulatory and industry guidelines.
Kristen Bolt is a data management expert with over 15 years of experience working with academic researchers, research administrators, and data contributors. As the former Program Manager for the Multi-Regional Clinical Trials Center she participated in and supported the design of a global clinical trial data sharing platform that will facilitate data sharing and transparency. In her previous positions at Harvard University and Harvard Medical School she designed a process and web application for sharing research metadata across multiple research administration stakeholders; thereby easing the organizational burden and accelerating the approval process for investigators. Her experience includes writing university and department policies to evaluate data sensitivity, data collection practices, and data management plans that also comply with state and federal regulations. She is also the Co-Chair of the Emerging Technologies, Ethics and Research subcommittee of the Harvard Clinical and Translational Science Award.
Kristen is a graduate of Harvard University.
Sulochana (Sulu) Gawande’s academic background is in clinical cancer research, having done her MS and Ph.D. work in characterization of human leukemia and lymphoma cells. Her career in oncology drug development started at Eli Lilly & Company in 1999. There Sulu gained understanding of oncology publication and submission documents. She established and managed teams of medical writers both in the US and India. Later as a Clinical Research Scientist (Lilly), she successfully partnered with the clinical lead physician to build a program to test a new Lilly compound for the treatment of colorectal cancer.
As a submission management and regulatory lead in Novartis Oncology (2008-2013), Sulu submitted and gained approval of INDs, led many interactions with the FDA and Health Authorities, and guided teams in the preparation of various regulatory documents including the DSUR, IBs, responses to deficiency or clinical hold, etc. Additionally, she supervised large teams of medical writers in India and the U.S., managed the disclosure process for Novartis oncology studies, and contributed to the strategy and review of commercial and regulatory documents.
Since May 2013, Sulu has been the Head of Oncology Medical Writing and an executive reviewer for all oncology publications at Eisai. She has supervised three regulatory submissions and working on the fourth one. Sulu is also leading the ct.gov and EudraCT disclosure team and the data transparency process. With her passion for oncology and her experience in clinical, regulatory, and scientific communications, she continues to improve the quality of submission documents and the disclosure process at Eisai.
Julie Holtzople is the Clinical Trial Transparency Operations Director at AstraZeneca. Julie is responsible for developing and implementing the processes, standards, systems and tools to ensure all AstraZeneca Clinical Trial Transparency policies and standards are fully realized. Currently, Julie is spending a lot of time working on clinical data and document anonymization to support legislation such as EMA Policy 0070. Prior to working at AstraZeneca, Julie spent almost a decade working as a consultant for Ernst & Young and Booz Allen Hamilton. Julie is a graduate of Virginia Tech.
Dr. Oladayo Oyelola is Director of Clinical Trial Information Disclosure at Daiichi-Sankyo, Inc. He coordinates and is accountable for corporate strategy and operations of global clinical trial information disclosure and data sharing activities including internal training, process improvements and clinical trial transparency regulatory policy intelligence. He has also served in the same capacity at Sanofi Pasteur Inc., the Vaccine Division of Sanofi and as Head of the Clinical Medical Writing Group, leading regulatory writing activities on clinical projects and clinical study teams for novel vaccine and pharmaceutical products for the US, EU and other international regulatory submissions and marketing approvals.
Dr. Oyelola holds a B.S. in Biochemistry, M.S. in Applied (Nutrition) Chemistry, and Ph.D. in Clinical Chemistry along with professional certifications of the National Registry of Certified Chemists and the American Society for Clinical Pathologists.
He is a recipient of The Rockefeller Foundation Special Postdoctoral Fellowship Award and the National Mentor Role Model Award/Citation of the Minority Access Inc/Office of Minority Health, National Institutes of Health.
He has over 30 years’ experience in clinical and pharmaceutical research and development activities, including years of college undergraduate and graduate teaching and biomedical research. He is a member of the American Association for Clinical Chemists, the American Society for Clinical Pathology, and the Drug Information Association.
Liz is Senior Director, Global Lead, Transparency and Data Sharing at UCB. She relocated from the U.K. to the U.S. in 2009 and is currently based in Maryland. She is responsible for establishing the strategic framework, guiding principles, and corporate policies that inform transparency and responsible data sharing. In addition, she is responsible for aligning best practices that will enable current and future global disclosure requirements including Global Clinical Trial Registration & Results Disclosure, Clinical Data Sharing, Lay Summaries, and other Transparency-related activities. Liz represents UCB on the TransCelerate workstream for Clinical Data Transparency and is also involved with sharing data for secondary research via ClinicalStudyDataRequest.com (CSDR). Prior to this role in Transparency, Liz had more than 20 years’ experience working as a statistician in the pharmaceutical industry and has an M.Sc. in Applied Statistics.
Nate received his Bachelor of Science in Biochemistry from the University of Michigan and a Master of Science Administration in research from Central Michigan University. He performed research at the University of Michigan and then merged into medical writing at MMS Holdings, a CRO after graduation. While at MMS Holdings, Nate fell into clinical disclosure and helped to develop and grow the disclosure department. After MMS, Nate spent a brief time in study management for the Alliance of Clinical Trials in Oncology before landing back in the disclosure world at Takeda. Nate has now been with Takeda for two years leading the disclosure department and helping with data transparency and lay summaries.
Laura Troast is Director of Clinical Trial Registration and Results Disclosure in the Clinical Data Disclosure and Transparency department at Merck & Co., Inc. Over the past ten years, Laura has overseen activities surrounding the registration and disclosure of results for Merck studies on ClinicalTrials.gov, EudraCT and ENCePP. Her concentration is in leveraging data integrity technical solutions in balance with the Microsoft Office suite of applications. She holds a B.S. in Biochemistry & Molecular Biology from Penn State University and an M.S. in Regulatory Affairs for Drugs, Biologics, and Medical Devices from Northeastern University.
Lauryn Uribe is an Associate Manager at Gilead Sciences in the Disclosures & Transparency group. Along with another colleague, she coordinates and leads all clinical trial disclosures activities including registration and results submissions, process and standards development, and training. She has approximately five years of experience in disclosures and transparency and over 12 years of experience in the biopharmaceutical industry. Using her MBA, she has streamlined processes, created efficiencies, and helped in developing an entirely in-house process that works.
Thomas is responsible for the product strategy of PharmaCM, TrialScope’s Clinical Trial Transparency Solution, which was acquired from Deloitte. He has more than 19 years of experience with performance and content management solutions, specializing in applications for life sciences such as clinical trial disclosure, structured product labeling, and submissions management and has been a been on the PharmaCM team since 2007.
Prior to its acquisition of PharmaCM by TrialScope, Thomas served as the General Manager of PharmaCM at Deloitte and the Director of PharmaCM Product Management at Intrasphere Technologies before that. Before to joining Intrasphere, Thomas worked in leadership, client-facing positions for Revelwood Inc. and Shepherd Systems, focused on performance management solutions.